This license will enable Oxford Nanopore to enhance its DNA/RNA sequencing platform. "GR's novel negative enrichment approach has exciting potential synergy with Oxford Nanopore's platform," commented Dr. Gordon Sanghera, CEO of Oxford Nanopore.

The new approach to targeting long DNA fragments for sequence-specific enrichment will allow users of Oxford Nanopore technology to focus on specific genomic regions that are of interest in a multiplex manner. This will allow Oxford Nanopore to bring rapid, near-sample targeted sequencing to market.

GR's CRISPR-based enrichment platform provides next-generation targeted enrichment complementary to polymerase chain reaction and hybrid capture that can be applied to both long and short DNA fragments.

The terms of the nonexclusive license agreement were not disclosed.

Molecular barcoding of DNA identifies rare mutations in stem cells
Scientists have developed a new next-generation sequencing technique using molecular barcodes that can accurately detect a single genetic mutation in...

Genetic regulation of immune diseases starts at birth
Areas of the human genome may explain the early origins of chronic immune and inflammatory diseases that develop later in life, according to a study published...

DNA 'origami' informs coronavirus vaccine design
Strategically folded DNA arranged to mimic viral antigens -- known as DNA "origami" -- may produce strong immune responses, according to a June 29 report...